Marcolin and the AIRC Foundation join forces: a two-year agreement to support cancer research and promote the training of young talents in the fight against breast cancer
Marcolin and the AIRC Foundation for cancer research have signed a two-year agreement for 2024 and 2025, dedicated to supporting scientific research. Through this partnership, Marcolin commits to funding a scholarship for the training of a young researcher, thereby making a concrete contribution to cancer research, with a particular focus on breast cancer.
In addition to the donation, starting in October—the month of the pink ribbon, which over the years has become the symbol of prevention and research into the most common cancer among women—Marcolin will engage its employees in a program to raise awareness and promote research and prevention. Every month, AIRC will share information and advice with employees to encourage a healthy lifestyle: don't smoke, exercise regularly, choose a healthy and balanced diet, and participate in recommended screenings for early diagnosis. The goal is to turn each individual into a wellness ambassador, both for themselves, their families, and their colleagues.
This agreement is part of a broader vision of social responsibility that Marcolin has been pursuing for years, committed to initiatives that value the well-being and centrality of people while creating sustainable value over time.
“As a Group, we are proud to support the AIRC Foundation on such a crucial topic as breast cancer research. We believe in the importance of scientific research as a driving force for progress, which is why we have chosen to invest in talents capable of transforming ideas into opportunities for society and individuals. At Marcolin, about 60% of our employees are women: promoting awareness of the prevention of the most common female cancer within our workplace is something we feel is our duty,” commented Clara Magnanini, Group Communication & ESG Director at Marcolin.
“Thanks to research, about 88% of women diagnosed with breast cancer today are alive five years after diagnosis. However, the challenge remains open for patients with the most aggressive forms, for whom treatments are not yet effective enough. With the support of the campaign’s donors and partners, we can tackle the final mile that separates us from the ultimate goal: curing all women. A goal that seems close, but the last mile is always the hardest, requiring even greater commitment from researchers, as this is where the most difficult obstacles lie,” commented Chiara Occulti, Chief Marketing & Fundraising Officer at the AIRC Foundation.
